Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fimepinostat in Relapsed/Refractory DLBCL
NCT02674750Phase 2Completed
- Sponsor
- Curis, Inc.
- Start
- Jul 2016
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of fimepinostat in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by Curis, Inc. Primary endpoint: Objective Response Rate at 2 years. Started Jul 2016; status: completed.
02
Drugs
fimepinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02674750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02674750.